newsfilter
← Latest News
GlobeNewswire·

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key